Trial Profile
Pharmacodynamic assay after single dose of gefitinib in resected adenocarcinoma of the lung
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 18 Apr 2021 Status changed from recruiting to discontinued.
- 17 Apr 2013 New trial record